Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort
- 5 March 2026
- journal article
- research article
- Published by Elsevier in Heart Rhythm
- Vol. 23 (8) , e1372-e1382
Abstract
No abstract availableKeywords
Funding Information
- National Cheng Kung University Hospital
This publication has 29 references indexed in Scilit:
- New-onset atrial fibrillation and history of ischemia-induced ventricular fibrillation indicate arrhythmic vulnerability during ST-elevation myocardial infarctionHeart Rhythm, 2025
- Risk factors associated with ventricular fibrillation during first ST-elevation myocardial infarction: Individual participant data analysis of 3 prospective case-control studiesHeart Rhythm, 2025
- The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery diseaseInternational Journal of Cardiology, 2024
- CAST: A study that rocked the cardiology world and became the poster child for evidence-based medicineHeart Rhythm, 2024
- Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery diseaseAmerican Heart Journal, 2022
- Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery DiseaseAmerican Journal of Cardiovascular Drugs, 2021
- Adverse Outcomes Associated with Pre-Existing and New-Onset Atrial Fibrillation in Patients with Acute Coronary Syndrome: A Retrospective Cohort StudyCardiology and Therapy, 2019
- Prognostic Impact of Types of Atrial Fibrillation in Acute Coronary SyndromesThe American Journal of Cardiology, 2009
- Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosisAmerican Heart Journal, 2008
- Prescribing AmiodaroneJAMA, 2007